Literature DB >> 19455045

Hepatic venous pressure gradient can predict the development of hepatocellular carcinoma and hyponatremia in decompensated alcoholic cirrhosis.

Moon Young Kim1, Soon Koo Baik, Chang Jin Yea, Il Young Lee, Hye Jung Kim, Kyong Won Park, Hearn Kook Kim, Ki Tae Suk, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Seung Hwan Cha, Young Ju Kim, Sang Baek Koh, Sei Jin Chang.   

Abstract

OBJECTIVE: Portal hypertension is closely associated with serious complications of cirrhosis, which contribute to bad prognosis. Hepatocellular carcinoma (HCC) and low serum sodium (SNa) are manifestations of end-stage liver disease and are associated with poor survival in decompensated cirrhosis patients. We aimed to determine the relationship between hepatic venous pressure gradient (HVPG) and the development of HCC or low SNa in decompensated alcoholic cirrhosis patients.
METHODS: Child-Pugh scores, Model for End-Stage Liver Disease scores, and HVPG at baseline, and the development of HCC or low SNa (SNa <130 mEq/l) during follow-up were analyzed prospectively in 170 patients with decompensated alcoholic cirrhosis from December 1999 to January 2008 (mean follow-up period of 33.9+/-27.9 months). The predictive value of different risk factors for the development of HCC and low SNa and survival were investigated.
RESULTS: Twenty-four patients developed HCC during the follow-up period. In the multivariate analysis, only baseline HVPG greater than 15 mmHg was an independent predictive factor for the development of HCC (relative risk=1.128, P<0.05) and which showed a significantly shorter time for the development of HCC on the Kaplan-Meier analysis. Twenty patients developed low SNa during follow-up. Initial HVPG was also an independent predictive factor for the new development of low SNa in the multivariate analysis (relative risk=1.169, P<0.05) and which also showed significantly shorter times for the development of low SNa on the Kaplan-Meier analysis.
CONCLUSION: In decompensated alcoholic cirrhosis, HVPG may be a useful predictive factor for the development of HCC and low SNa.

Entities:  

Mesh:

Year:  2009        PMID: 19455045     DOI: 10.1097/MEG.0b013e32832a21c1

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  22 in total

Review 1.  Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement.

Authors:  Ki Tae Suk; Dong Joon Kim
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

3.  Portal hypertensive gastropathy: correlation with portal hypertension and prognosis in cirrhosis.

Authors:  Moon Young Kim; Hoon Choi; Soon Koo Baik; Chang Jin Yea; Chan Sik Won; Jong Won Byun; So Yeon Park; Yong Hwan Kwon; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Young Ju Kim; Seung Hwan Cha; Sei Jin Chang
Journal:  Dig Dis Sci       Date:  2010-04-21       Impact factor: 3.199

4.  Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.

Authors:  Jae Hyun Kim; Jung Min Kim; Youn Zoo Cho; Ji Hoon Na; Hyun Sik Kim; Hyoun A Kim; Hye Won Kang; Soon Koo Baik; Sang Ok Kwon; Seung Hwan Cha; Young Ju Kim; Moon Young Kim
Journal:  Clin Mol Hepatol       Date:  2014-12-24

5.  Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis.

Authors:  Yoon Ok Jang; Mee-Yon Cho; Chae-Ok Yun; Soon Koo Baik; Kyu-Sang Park; Seung-Kuy Cha; Sei Jin Chang; Moon Young Kim; Yoo Li Lim; Sang Ok Kwon
Journal:  Stem Cells Transl Med       Date:  2016-06-30       Impact factor: 6.940

6.  Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt.

Authors:  Yuo-Chen Kuo; Maureen P Kohi; David M Naeger; Ricky T Tong; K Pallav Kolli; Andrew G Taylor; Jeanne M Laberge; Robert K Kerlan; Nicholas Fidelman
Journal:  Cardiovasc Intervent Radiol       Date:  2013-07-18       Impact factor: 2.740

7.  Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage.

Authors:  Hyo Keun Jeon; Moon Young Kim; Soon Koo Baik; Hong Jun Park; Hoon Choi; So Yeon Park; Bo Ra Kim; Jin Heon Hong; Ki Won Jo; Seung Yong Shin; Jung Min Kim; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Young Ju Kim; Seung Hwan Cha; Dong Joon Kim; Ki Tae Suk; Gab Jin Cheon; Young Don Kim; Dae Hee Choi; Sung Joon Lee
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

8.  Level and Value of T Cell-derived Circulating Microparticles in Liver Cirrhosis Patients.

Authors:  Chih-Hung Chen; Chia-Lo Chang; Kuan-Hung Chen; Ben-Chung Cheng; Hong-Hwa Chen; John Y Chiang; Pei-Hsun Sung; Hon-Kan Yip
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

9.  Levels and values of circulating endothelial progenitor cells, soluble angiogenic factors, and mononuclear cell apoptosis in liver cirrhosis patients.

Authors:  Chih-Hung Chen; Li-Teh Chang; Wei-Chih Tung; Yung-Lung Chen; Chia-Lo Chang; Steve Leu; Cheuk-Kwan Sun; Tzu-Hsien Tsai; I-Ting Tsai; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  J Biomed Sci       Date:  2012-07-18       Impact factor: 8.410

10.  Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis.

Authors:  Yoon Ok Jang; Baek Gyu Jun; Soon Koo Baik; Moon Young Kim; Sang Ok Kwon
Journal:  Clin Mol Hepatol       Date:  2015-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.